Assessment of propranolol efficacy on pediatric haemangioma: an experimental study
Keywords:Hemangioma, Propranolol, Treatment effect, Infants, Ardabil
Background: Hemangioma is the most common vascular tumor in infancy. Recent studies show Propranolol efficacy on hemangioma treatment due to its rapid effect and a few side effects. The aim of this study was to assessment the efficacy of Propranolol on pediatric haemangioma.
Methods: This quasi-experimental study was done on 20 children refer to Bu-Ali hospital. Treatment indications were multiple hemangioma, organ malfunction and enlarging hemangioma. Treatment of patients was started with 1 mg/kg/day and then increased to 3 mg/kg/day and continued for 6 month. Collected data analyzed by statistical methods in SPSS-19.
Results: Patients mean age was 23.2 ± 11.2 months. 65% of them were female and 35% were male. The mean size of damages was 4.9 ± 3.3 cm. 70% of patients had acceptable response with more than 50% and 30% had partial response with less than 50% decrease in size. This effect is similar to corton effect (about 84%) but with less side effects.
Conclusions: This study showed that Propranolol has acceptable effect on decreasing size of hemangioma and could be recommended as a first choice of hemangioma treatment.
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168-73.
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412-22.
Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138:1567-76.
Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L. Infantile hemangiomas: current knowledge, future directions: proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22:383-406.
Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137:1208-13.
Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson textbook of pediatrics. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.
Chamlin SL, Haggstrom AN, Drolet BA, Baselga E, Frieden IJ, Garzon MC, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007;151(6):684-9.
Akhavan A, Zippin JH. Current treatments for infantile hemangiomas. J Drugs Dermatol. 2010;9(2):176-80.
Léauté L. Propranolol for Severe Hemangiomas of Infancy. N Engl J Med. 2008;358(24):140-9.
Propranolol In Pediatric Hemangioma; avilable at: www.health-forums.com/alt-support-cancer/propranolol-pediatric-heman. 2011.
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358(24):2649-51.
Shayan Yasaman R. Use of propranolol in treating hemangiomas. Canadian Family Physician March 2011;57:3302-3
Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics. 2008;122:65-74.
Sehgal VN. Textbook of clinical dermatology, 4th ed, Jaypee, New denli. 2004;220-224.
Habif TP. Clinical dermatology. London: Mosby. 2009;691-93.
Melo-Gomes JA. Problems related to systemic glucocorticoid therapy in children. J Rheumatol Suppl. 1993;37:35-9.
Zimmermann AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy of infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol. 2010;74(4):338-42.
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.Plast Reconstr Surg. 1982;69:412-22.
Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol. 2011;120(10):686-95.
Eichenfield LF, Frieden IJ, Esterly NB. Textbook of Neonatal Dermatology. Philadelphia, Pa: WB Saunders Co. 2001:324-353.
Fridman G, Grieser E, Hill R, Khuddus N, Bersani T, Slonim C. Propranolol for the treatment of orbital infantile hemangiomas. Ophthal Plast Reconstr Surg. 2011;27(3):190-4.
Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120(4):676-81.
Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A.Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS. 2010;14(3):251-6.
Kim LH, Hogeling M, Wargon O, Jiwane A, Adams S. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg. 2011;46(4):759-63
Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012;29(2):154-9.
Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad Dermatol. 2012;67(6):1210-3.
Chung SH, Park DH, Jung HL, Shim JW, Kim DS. Successful and safe treatment of hemangioma with oral propranolol in a single institution. Korean J Pediatr. 2012;55(5):164-70.
Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222-4.
Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol. 2011;28(6):649-54.
Xu SQ, Jia RB, Zhang W, Zhu H, Ge SF, Fan XQ. Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review. World J Pediatr. 2013;9(3):221-9.